|
|
||||||||
,1
* Department of Veterinary Biosciences and
Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, Illinois 61802
1 To whom requests for reprints should be addressed at Department of Veterinary Biosciences, University of Illinois, 2001 S. Lincoln Ave., Urbana, IL 61802. E-mail: p-cooke{at}uiuc.edu
| Abstract |
|---|
|
|
|---|
Key Words: hormones phytoestrogen adipose tissue adipogenesis
| Introduction |
|---|
|
|
|---|
Hormones are major regulators of adipose tissue and are critical for adipocyte development and function. An extensive array of hormones and growth factors modulate adipocyte development and activity, including growth hormone, thyroid hormone, glucocorticoids, catecholamines, glucagon, insulin, and insulin-like growth factor. Estrogen has long been recognized as a major factor in regulating adipose development and deposition in females. In recent years, it has become clear that estrogens role in adipose biology may be broader and more complex than initially appreciated. Estrogen is now known to play an important role in regulating adipose deposition in males and recently has been shown to be an important factor in the determination of adipocyte number, indicating that it regulates key developmental events in adipogenesis. The classical estrogen receptor, estrogen receptor (ER)
, appears to be the major regulator of adipose tissue, but recent results have also indicated a possible role for the more recently discovered estrogen receptor, ERß. This review will summarize estrogen effects on adipose tissue and will concentrate on the more recent developments in this area that have contributed to our still-evolving view of the role of estrogen in the regulation of this critical tissue.
| Adipose Tissue Is Sexually Dimorphic and Is Regulated by Estrogen |
|---|
|
|
|---|
|
The extensive gender-related differences seen in humans between subcutaneous and visceral fat in terms of estrogen responsiveness are not seen in rodents. Likewise, the pronounced sexual dimorphism in adipose tissue seen in humans does not occur in rodents, although rodents show marked sexual dimorphism in terms of adipose response to caloric restriction, exercise, and treatment with PPAR
agonists (1315).
Further complicating an overall understanding of the role of estrogen in adipose tissue, adipose ER varies by depot and with different physiological states. The variations in ER expression in the adipose depots correlate with clear differences in the physiological responsiveness of adipocytes from various fat pads to estrogen (16). ER expression in adipose tissue shows changes with age, and ER expression is altered in response to various physiological states such as obesity (16).
Understanding the role of ER signaling in adipose tissue also obviously necessitates taking into account the large developmental changes in estrogen concentrations in humans and laboratory animals during their lifetimes. For example, in women there are minimal levels of E2 in infancy and childhood, a sharp rise during puberty, continued high concentrations during the remainder of the reproductive lifetime, and then a decline to low levels during menopause and throughout subsequent life. Likewise, there normally is a marked difference in estrogen concentration between men and women. Therefore, when analyzing the overall role of estrogen signaling in adipose tissue, these variations in receptor levels and response or ligand availability must always be taken into account.
| ER Expression in Adipose Tissue of Humans and Rodents |
|---|
|
|
|---|
and ERß (1719), indicating that estrogen signaling may occur through either of these ERs in adipose tissue. In addition, there is also evidence that 17ß-estradiol (E2) can act through the less well characterized membrane ER in adipocytes to induce rapid effects that do not involve the classical nuclear ERs (20).
Previous work has focused on the ability of estrogen to induce functional and morphological changes in adipocytes, though other literature clearly indicates that many, if not all, major cell types in adipose tissue are potentially direct estrogen targets. For example, a number of studies using human and animal tissue have indicated that ER is expressed in preadipocytes (18, 21), so E2 can potentially regulate preadipocyte development as well as act directly on adipocytes. In addition to the preadipocyte/adipocyte lineage, ER
or ß are also expressed in other cell types found in adipose tissue, such as vascular endothelium, vascular smooth muscle, and macrophages (2224). Therefore, effects on many cell types must be considered in an analysis of overall estrogen effects on adipose tissue activity and lipid stores.
Estrogens are also capable of producing effects on adipose tissue by acting indirectly through other tissues that regulate appetite, energy expenditure or metabolism. ERs are widely distributed in the hypothalamus, the primary site in the brain that regulates energy balance, and effects of estrogens on both energy intake and expenditure are well known, as described later in this review. In addition, ERs are also present in organs such as the liver, where estrogen effects can produce metabolic changes that ultimately affect adipose deposition and overall adipose mass.
Although the literature has concentrated on estrogen effects in adipose tissue of females, adipocytes from males (of humans and other species) express ER at levels similar to those seen in females (21). Despite the typically greater circulating E2 concentrations in females, males from a variety of species also have measurable circulating concentrations of E2. Adipose tissue in males is therefore a direct target of estrogenic stimulation, as demonstrated by the following section highlighting extensive adipose changes in males lacking ER
.
In summary, estrogen can have direct effects on adipocytes and other cell types in adipose tissue of both sexes, as well as indirect effects on other tissues (e.g., brain, liver) that regulate adipose tissue. Understanding the totality of estrogen effects on adipose tissue involves elucidation of the roles of estrogen in the various target tissues that can effect adipose deposition.
| Estrogen Regulates Adipose Tissue Deposition in Adult Females |
|---|
|
|
|---|
|
The effects of loss of estrogen on adipose tissue in female rodents closely parallels those described in women. There is an extensive literature documenting increases in adipose tissue in rats and mice following ovariectomy (25), and female ER
knockout (
ERKO) mice have large increases in adipose mass (26). The adipose changes in humans, rodents, or other animals caused by a lack of estrogen can be reversed with estrogen replacement (27), and decreases in adipose tissue are one significant benefit of hormone replacement therapy given to postmenopausal women (28).
| Direct Effects of Estrogen on Adipocytes |
|---|
|
|
|---|
E2 can indirectly affect lipolysis by inducing the lipolytic enzyme hormone-sensitive lipase (31) or by increasing the lipolytic effects of epinephrine (32). Fatty acid-ß oxidation might also be increased, which might contribute to the decrease in adipose tissue deposition induced by E2 (33). Contrary to its overall antilipogenic and lipolytic effect, estrogen site-specifically attenuates the effects of
2A-adrenergic receptors in the subcutaneous fat cells of humans and decreases lipolysis; this effect could partially account for the increased deposition of subcutaneous adipose tissue in women compared to men (34).
| Estrogen Effects on Energy Intake and Expenditure |
|---|
|
|
|---|
ERKO mice show a decrease in energy expenditure, indicating that estrogens actions on energy metabolism are through ER
(26). In addition to its direct effects on the hypothalamus described above, estrogen may also regulate the production or response to adipose hormones such as leptin and, through this mechanism, affect processes such as food consumption and energy metabolism. Some data have indicated that the increase in adipose stores following estrogen withdrawal leads to increased circulating leptin, indicating that the leptin increase following loss of estrogen is secondary to increased adipose deposition, rather than directly driven by the lack of estrogen (36). However, other results (37, 38) have indicated that estrogen can regulate leptin and there is presently no consensus on the role of estrogen in regulating leptin.
Leptin is produced primarily by adipocytes and it acts through its receptors (Ob-R) in the hypothalamus to ultimately produce changes in energy intake and expenditure that are involved in the homeostatic control of adipose mass. The critical long form of the leptin receptor (Ob-Rb) in the hypothalamus is modulated by estrogen status, with lack of estrogen for approximately 5 months causing a decrease in Ob-Rb, which may partially explain continued obesity following loss of estrogen despite large increases in circulating leptin induced by ovariectomy (36).
Estrogens have effects on other organs, such as the liver, that are involved in various aspects of metabolism and that are altered in obesity. For example, estrogen effects on cholesterol uptake, biosynthesis, and catabolism have been documented in the aromatase knockout (ArKO) female, which lacks the enzymatic machinery to make estrogens, although these effects are sexually dimorphic and not seen in ArKO males (39).
Relative Roles of ER and ERß in Adipose Tissue
|
|---|
|
|
|---|
and ERß (17) necessitated work to ascertain the relative roles of ER
and ERß in adipose tissue.
ERKO mice show over a 100% increase in adipose tissue compared with wild-type (WT) mice (26) (Fig. 3
signaling in
ERKO mice, and the lack of endogenous E2 in the ArKO and FSH receptor knockout mice, which should lead to lack of signaling through both ER
and ERß, led to similar increases in adipose tissue. These results strongly indicate that ER
is the main regulator of estrogen effects on adipose tissue.
|
ERKO mice still express ERß and have tenfold increases in circulating E2 (43), which could cause increased E2/ERß signaling. To evaluate the potential role of E2/ERß signaling in adipose tissue,
ERKO mice were ovariectomized to determine whether loss of E2/ERß signaling in animals already lacking E2/ER
signaling induced any demonstrable change in adipose tissue or other parameters. Ovariectomized
ERKO mice showed a decrease in adipose tissue and body weight compared to sham-operated
ERKO mice, indicating that ERß might have an inhibitory effect on adipose deposition that is opposite that mediated through ER
(19). Therefore, although ER
is the predominant modulator of estrogenic effects in adipose tissue, ERß may also play a role in the effects of estrogen on adipocytes. | Effects of Xenoestrogens on Adipose Tissue |
|---|
|
|
|---|
or ß at varying levels and initiating transcription. Humans consuming soy products and supplements are exposed to high quantities of phytoestrogens, which are plant-derived estrogens. Genistein and diadzein are the principal phytoestrogen components in soy. Humans and animals are also exposed to varying degrees of equol, which is a metabolite of diadzein. Dietary genistein fed to mice results in serum-genistein concentrations comparable to those in humans consuming phytoestrogens and has an antilipogenic effect on adipose deposition (Fig. 2In vitro studies have shown that genistein may also induce effects on adipogenesis, with inhibitory effects at low concentrations (49, 50) and stimulatory effects at high concentrations (50). These results indicate that genistein may have the capacity to alter adipocyte number either up or down at various concentrations, although the high levels of genistein required to induce stimulatory effects on adipogenesis make the physiological relevance of this finding questionable.
There have been varying reports on the effect of selective-estrogen receptor modulators such as tamoxifen and raloxifene on adipose tissue. The potential effects of these compounds on adipose tissue are important because of their widespread use for breast cancer prevention and treatment. Tamoxifen has been reported to reduce adipose tissue deposition and LPL activity in adipose tissue of rats in the absence of E2 (51). However, contrary to this report, women on tamoxifen treatment for breast cancer show an increase in body fat (52). A recent report showed that raloxifene inhibited the ovariectomy-induced adipose and serum leptin increase in rats similar to E2 (36). Likewise, EM-652, which is a pure antiestrogen in human breast and uterine cancer cells, appears to function as an estrogen agonist in adipose tissue, where it has antilipogenic effects, and it also produces beneficial effects on insulin resistance (53). The effect of xenoestrogens on adipose tissue depends on the levels of endogenous estrogens, binding efficiency to ER
and ERß, and level of exposure (54). It appears that a number of selective-estrogen receptor modulators that have antiestrogenic effects in breast tissue may have beneficial estrogenic effects on adipose tissue. Clearly, more work is needed to understand the effects of these natural and man-made estrogen receptor agonists and antagonists on adipose tissue, and the ubiquity of these compounds in our environment and the extent of their use in human medicine emphasizes the importance of this area.
| Estrogens Regulates Adipose Development and Mass in the Male |
|---|
|
|
|---|
signaling pathway could have effects on male adipose tissue. However, for many years it was unclear whether E2 played a significant role in adipose development or function in the male. The development of
ERKO and ArKO mice provided a powerful tool to directly address the effects of loss of E2/ER
signaling both on male adipose tissue as well as on various metabolic parameters such as insulin resistance that are affected by a loss of E2/ER
signaling in women and females of other species.
Both male
ERKO and ArKO mice have modest increases in adult body weight compared to WT controls. Individual fat pad weights showed striking and age-related increases in
ERKO and ArKO males compared to WT males (26, 41). Fat pads in
ERKO males weigh 140%185% more than those in WT mice at days 270360 of age (26) (Fig. 3
), and similar increases were seen in ArKO males (41). The increase in adipose tissue was a result of both adipocyte hypertrophy and hyperplasia in the
ERKO (26) (Fig. 3
) and ArKO (33, 41) males. As described above, in females E2 has effects on cholesterol uptake, biosynthesis, and catabolism, but these effects are not seen in males (39). However, ArKO males have hepatic steatosis and alterations in triglyceride and fatty acid homeostasis (41), which can be reversed by E2 replacement (39), indicating that E2 has important effects on nonadipose tissues that modulate the obesity phenotype and the metabolic changes seen in these animals.
The effects of estrogen on adipose deposition seen in male rodents appear to be similar to those seen in human males lacking aromatase and the ability to produce endogenous estrogens (55). However, the rarity of the inactivating mutation of the gene encoding aromatase in human males means that only a handful of such cases are known, and thus conclusions have to be drawn cautiously. Men lacking aromatase tend to have increased body fat, insulin resistance, and a proclivity toward type II diabetes, and these conditions are improved by estrogen treatmentfindings that are totally consistent with the known role of estrogens in adipose deposition in laboratory rodents.
| Effects of Estrogen on Adipose Development |
|---|
|
|
|---|
Human and animal preadipocytes express both ER
and ß (18, 19, 21), as described above. E2 was originally reported to stimulate proliferation of human preadipocytes in the 1970s (56) and similar results have been obtained in a variety of species and experimental systems since that time. For example, Lea-Currie et al. (57) demonstrated that 1 µM E2 stimulated proliferation in the mouse NIH 3T3-L1 preadipocyte cell line. Similarly, Dieudonne et al (58) reported that E2 stimulated proliferation of subcutaneous rat preadipocytes from females, but not males. The rodent data indicating a stimulatory effect of E2 on preadipocyte proliferation is corroborated by human studies indicating that E2 stimulated proliferation of preadipocytes derived from men and women, though some sex-specific responses to E2 stimulation were noted (59).
Preadipocytes can remain undifferentiated, or they can differentiate into postmitotic fully differentiated adipocytes; this process is obviously critical in establishing final adipocyte number. Present literature indicates that E2 can have an effect on adipocyte differentiation, although the reports in this area are not entirely consistent. Studies with rat preadipocytes indicate that E2 stimulates differentiation of these cells into adipocytes (58). In contrast to these findings, other results have indicated that E2 can inhibit differentiation of adipocytes in the 3T3-L1 cell line (57). The inhibitory effects of estrogen on adipocyte differentiation reported in this study are consistent with numerous reports (49, 60, 61) that estrogen inhibits adipogenesis in primary bone marrow stromal cell cultures or bone marrow stroma cell lines.
Despite reports that E2 stimulates preadipocyte proliferation and conflicting reports on the effects of E2 on adipocyte differentiation, recent studies using both the
ERKO and ArKO gene knockout mouse models have clearly indicated that E2 normally has an inhibitory effect on overall adipocyte number. Heine et al. (26) reported that both male and female
ERKO mice have large increases in fat pad weights, as described above. There was a modest hypertrophy of the adipocytes in these animals, but the most striking change was an adipocyte hyperplasia. For example, adipocyte number was up to 170% greater in the fat pads of
ERKO compared to control mice, and adipocyte hyperplasia was seen in all fat pads examined. Similar increases were seen in ArKO mice (33, 41). Thus, lack of estrogen signaling in these knockout animals led to large increased adipocyte numbers, indicating that estrogen normally plays an inhibitory role during adipogenesis to limit ultimate adipocyte number (Fig. 3
).
| Neonatal Estrogen Treatment Decreases Adult Adipose Mass and Adipocyte Number |
|---|
|
|
|---|
ERKO and ArKO mice indicated that lack of signaling through ER
could result in large increases in adipocyte number and obesity. The converse question, whether exposure to exogenous estrogens during development can cause decreases in adipocyte number, is also an important one that has clinical implications and that is presently being addressed in a number of laboratories. Preliminary studies have shown that neonatal treatment of rats and mice with synthetic estrogens such as diethyl-stilbestrol or E2 can result in large decreases in adipose mass (up to 90%) in these animals when they reach adulthood (62; Koosuru and Cooke, unpublished data). In addition, these decreases appear to result primarily from decreases in adipocyte number (Naaz, Goyal, and Cooke, unpublished data). Thus, early estrogen exposure produces decreases in adipocyte number, effects that are the opposite of those seen in
ERKO and ArKO mice, further indicating the critical role of ER
during the neonatal period in the establishment of adult adipocyte number. | How Does Estrogen Regulate Adipocyte Number? |
|---|
|
|
|---|
The process by which preadipocytes differentiate into adipocytes also involves cell proliferation, at least in the in vitro systems in which this is normally studied. This process represents another potential target in which a hormone such as E2 could act to alter ultimate adipocyte numbers. Knockout studies using animals lacking either the estrogen receptor ligand or the receptor itself indicate that the overall effect of abolishing ER signaling is to produce an adipocyte hyperplasia and obesity, but clearly additional work is required to elucidate the specific estrogen effects on the various developmental processes involved in adipogenesis.
Much of our understanding of adipogenesis comes from 3T3-L1 preadipocytes, which are initially fibroblastic but undergo adipogenic differentiation when confluent cultures are exposed to differentiation media. During differentiation, these cells undergo a period of proliferation, termed mitotic clonal expansion, characterized by increased cyclin expression. D- and E-type cyclins bind to their cyclin-dependent kinase (cdk) partners and play a critical role in cell-cycle progression from G1 to S. Functional activity of cyclin/cdk complexes is regulated by cyclin-dependent kinase inhibitors (CDKIs), which bind and inactivate cyclin/cdk complexes and therefore inhibit progression from G1 to S phase. CDKIs consist of two families, the Cip/Kip family (p27, p21, and p57) and the Ink4 family (64). Morrison and Farmer (65) reported that p27 and p21 decreased at the start of mitotic clonal expansion in 3T3-L1 preadipocytes, and termination of mitotic clonal expansion was accompanied by increases in both p27 and p21; these results indicate that p27 and p21 play an important role in adipogenesis of 3T3-L1 cells, but their role in adipogenesis in vivo has not been clear (66).
To test the hypothesis that p27 or p21 regulate adipocyte number, we have compared adipose development and metabolic parameters in p27 and p21 knockouts (p27KO and p21KO, respectively), p27/p21 double knockout and WT mice. At 120 days of age, inguinal and parametrial fat pads showed 80%, 90%, and 400% increases in wet weight in p27KO, p21KO, and double knockout mice, respectively, compared to WT (67). Adipocyte numbers in parametrial fat pads of p27KO, p21KO, and double knockout mice were 2-, 2-, and 6-fold those in WT, respectively. Despite these striking increases in adipocyte number, average adipocyte size was not significantly different in any of the groups, and the observed increases in adipose pad weights reflect the adipocyte hyperplasia that occurs with the loss of one or more of these CDKIs.
The important role for p27 and p21, separately and together, in regulating adipocyte number and adipose mass indicates that these CDKIs are potential targets for E2 or other hormonal signals that may result in alterations in final adipocyte number. In addition, other recent reports have demonstrated the critical role of proteins such as sirtuin 1 in regulating adipogenesis (68), and work to establish whether estrogen effects on adipocyte number are mediated through p27 and p21 or other target proteins that play critical roles in adipogenesis is ongoing.
| Summary and Conclusions |
|---|
|
|
|---|
|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Singhal, K. Shankar, T. M Badger, and M. J Ronis Hepatic gene expression following consumption of soy protein isolate in female Sprague-Dawley rats differs from that produced by 17{beta}-estradiol treatment J. Endocrinol., July 1, 2009; 202(1): 141 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Diamanti-Kandarakis, J.-P. Bourguignon, L. C. Giudice, R. Hauser, G. S. Prins, A. M. Soto, R. T. Zoeller, and A. C. Gore Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement Endocr. Rev., June 1, 2009; 30(4): 293 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Brewer, A. L. S. Dowling, M. A. Curran-Rauhut, P. W. Landfield, N. M. Porter, and E. M. Blalock Estradiol Reverses a Calcium-Related Biomarker of Brain Aging in Female Rats J. Neurosci., May 13, 2009; 29(19): 6058 - 6067. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Alexanderson, E. Eriksson, E. Stener-Victorin, M. Lonn, and A. Holmang Early postnatal oestradiol exposure causes insulin resistance and signs of inflammation in circulation and skeletal muscle J. Endocrinol., April 1, 2009; 201(1): 49 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Saleh, M. Al-Khanbashi, M. Al-Maarof, M. Al-Lawati, S. G Rizvi, and K. Cianflone Acylation-stimulating protein increases and correlates with increased progesterone levels during the luteal phase of the menstrual cycle Eur. J. Endocrinol., February 1, 2009; 160(2): 301 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Belsito, B. M. Vester, T. Keel, T. K. Graves, and K. S. Swanson Impact of ovariohysterectomy and food intake on body composition, physical activity, and adipose gene expression in cats J Anim Sci, February 1, 2009; 87(2): 594 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. K. Khor, M. H. Tong, Y. Qian, and W.-C. Song Gender-Specific Expression and Mechanism of Regulation of Estrogen Sulfotransferase in Adipose Tissues of the Mouse Endocrinology, November 1, 2008; 149(11): 5440 - 5448. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Monteiro, M. Assuncao, J. P. Andrade, D. Neves, C. Calhau, and I. Azevedo Chronic Green Tea Consumption Decreases Body Mass, Induces Aromatase Expression, and Changes Proliferation and Apoptosis in Adult Male Rat Adipose Tissue J. Nutr., November 1, 2008; 138(11): 2156 - 2163. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-J. Lee, H. Lin, C.-W. Liu, M.-H. Wu, W.-J. Liao, H.-H. Chang, H.-C. Ku, Y.-S. Chien, W.-H. Ding, and Y.-H. Kao Octylphenol stimulates resistin gene expression in 3T3-L1 adipocytes via the estrogen receptor and extracellular signal-regulated kinase pathways Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1542 - C1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Cederroth, M. Vinciguerra, A. Gjinovci, F. Kuhne, M. Klein, M. Cederroth, D. Caille, M. Suter, D. Neumann, R. W. James, et al. Dietary Phytoestrogens Activate AMP-Activated Protein Kinase With Improvement in Lipid and Glucose Metabolism Diabetes, May 1, 2008; 57(5): 1176 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Konhilas and L. A. Leinwand The Effects of Biological Sex and Diet on the Development of Heart Failure Circulation, December 4, 2007; 116(23): 2747 - 2759. [Full Text] [PDF] |
||||
![]() |
M. Badeau, V. Vihma, T. S. Mikkola, A. Tiitinen, and M. J. Tikkanen Estradiol Fatty Acid Esters in Adipose Tissue and Serum of Pregnant and Pre- and Postmenopausal Women J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4327 - 4331. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Alexanderson, E. Eriksson, E. Stener-Victorin, T. Lystig, B. Gabrielsson, M. Lonn, and A. Holmang Postnatal Testosterone Exposure Results in Insulin Resistance, Enlarged Mesenteric Adipocytes, and an Atherogenic Lipid Profile in Adult Female Rats: Comparisons with Estradiol and Dihydrotestosterone Endocrinology, November 1, 2007; 148(11): 5369 - 5376. [Abstract] [Full Text] [PDF] |
||||
![]() |
H O Goyal, T D Braden, C S Williams, and J W Williams Role of estrogen in induction of penile dysmorphogenesis: a review Reproduction, August 1, 2007; 134(2): 199 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Gowri, S. Sengupta, S. Bertera, and B. S. Katzenellenbogen Lipin1 Regulation by Estrogen in Uterus and Liver: Implications for Diabetes and Fertility Endocrinology, August 1, 2007; 148(8): 3685 - 3693. [Abstract] [Full Text] [PDF] |
||||
![]() |
H O Goyal, T D Braden, P S Cooke, M A Szewczykowski, C S Williams, P Dalvi, and J W Williams Estrogen receptor-{alpha} mediates estrogen-inducible abnormalities in the developing penis Reproduction, May 1, 2007; 133(5): 1057 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Jaubert, N. Mehebik-Mojaat, D. Lacasa, D. Sabourault, Y. Giudicelli, and C. Ribiere Nongenomic Estrogen Effects on Nitric Oxide Synthase Activity in Rat Adipocytes Endocrinology, May 1, 2007; 148(5): 2444 - 2452. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Penza, C. Montani, A. Romani, P. Vignolini, B. Pampaloni, A. Tanini, M. L. Brandi, P. Alonso-Magdalena, A. Nadal, L. Ottobrini, et al. Genistein Affects Adipose Tissue Deposition in a Dose-Dependent and Gender-Specific Manner Endocrinology, December 1, 2006; 147(12): 5740 - 5751. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Titolo, F. Cai, and D. D. Belsham Coordinate Regulation of Neuropeptide Y and Agouti-Related Peptide Gene Expression by Estrogen Depends on the Ratio of Estrogen Receptor (ER) {alpha} to ER{beta} in Clonal Hypothalamic Neurons Mol. Endocrinol., September 1, 2006; 20(9): 2080 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Chen, M.-J. Lee, H.-H. Chang, P.-F. Hung, and Y.-H. Kao 17{beta}-Estradiol Stimulates Resistin Gene Expression in 3T3-L1 Adipocytes via the Estrogen Receptor, Extracellularly Regulated Kinase, and CCAAT/Enhancer Binding Protein-{alpha} Pathways Endocrinology, September 1, 2006; 147(9): 4496 - 4504. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. D'Eon, S. C. Souza, M. Aronovitz, M. S. Obin, S. K. Fried, and A. S. Greenberg Estrogen Regulation of Adiposity and Fuel Partitioning: EVIDENCE OF GENOMIC AND NON-GENOMIC REGULATION OF LIPOGENIC AND OXIDATIVE PATHWAYS J. Biol. Chem., October 28, 2005; 280(43): 35983 - 35991. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |